2 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Genetic Disease, X-Linked: new trials by email Literature Review of Genetic Disease, X-Linked trials Research Report on Genetic Disease, X-Linked
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO) Zeleciment Rostudirsen (DYNE-251), Placebo - Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne | Phase 3 | Recruiting | Dyne Therapeutics | 90 | 2026-06-01 | 2026-05-27 |
| Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes Granuloma, Granulomatous Disease, Chronic | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 850 | 1994-02-27 | 2026-10-13 |
Genetic Diseases, Inborn (2) · Genetic Diseases, X-Linked (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Granuloma (1) · Granulomatous Disease, Chronic (1) · Infections (1) · Muscular Dystrophies (1) · Muscular Dystrophy, Duchenne (1) · Myotonic Dystrophy (1) · Neuromuscular Diseases (1)
Chronic Disease (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Heredodegenerative Disorders, Nervous System (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Leukocyte Disorders (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Muscular Diseases (1) · Muscular Disorders, Atrophic (1) · Musculoskeletal Diseases (1) · Myotonic Disorders (1)
Dyne Therapeutics (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (2)
2025 (1)